Hepatic carboxylesterase 1 is essential for both normal and farnesoid X receptor‐controlled lipid homeostasis

Nonalcoholic fatty liver disease (NAFLD) is one of the major health concerns worldwide. Farnesoid X receptor (FXR) is considered a therapeutic target for treatment of NAFLD. However, the mechanism by which activation of FXR lowers hepatic triglyceride (TG) levels remains unknown. Here we investigate...

Full description

Saved in:
Bibliographic Details
Published inHepatology (Baltimore, Md.) Vol. 59; no. 5; pp. 1761 - 1771
Main Authors Xu, Jiesi, Li, Yuanyuan, Chen, Wei‐Dong, Xu, Yang, Yin, Liya, Ge, Xuemei, Jadhav, Kavita, Adorini, Luciano, Zhang, Yanqiao
Format Journal Article
LanguageEnglish
Published United States Wiley Subscription Services, Inc 01.05.2014
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Nonalcoholic fatty liver disease (NAFLD) is one of the major health concerns worldwide. Farnesoid X receptor (FXR) is considered a therapeutic target for treatment of NAFLD. However, the mechanism by which activation of FXR lowers hepatic triglyceride (TG) levels remains unknown. Here we investigated the role of hepatic carboxylesterase 1 (CES1) in regulating both normal and FXR‐controlled lipid homeostasis. Overexpression of hepatic CES1 lowered hepatic TG and plasma glucose levels in both wild‐type and diabetic mice. In contrast, knockdown of hepatic CES1 increased hepatic TG and plasma cholesterol levels. These effects likely resulted from the TG hydrolase activity of CES1, with subsequent changes in fatty acid oxidation and/or de novo lipogenesis. Activation of FXR induced hepatic CES1, and reduced the levels of hepatic and plasma TG as well as plasma cholesterol in a CES1‐dependent manner. Conclusion: Hepatic CES1 plays a critical role in regulating both lipid and carbohydrate metabolism and FXR‐controlled lipid homeostasis. (Hepatology 2014;59:1761–1771)
Bibliography:These authors contributed equally to this work.
See Editorial on Page 1665
Potential conflict of interest: Dr. Adorini is employed by and owns stock in Intercept.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0270-9139
1527-3350
DOI:10.1002/hep.26714